Wegovy oral pill: A new era in weight loss treatment
On January 5, 2026, following FDA approval, Novo Nordisk’s Wegovy oral pill became available to patients across America for weight loss management.
Why it matters: For the first time in history, a GLP-1 pill has been approved for consumers as a weight-loss treatment.
Before the approval of the Wegovy oral pill was announced, patients could only take GLP-1s via injection when seeking weight loss management. While another oral pill is on the market, it is only FDA approved as a Type 2 diabetes management tool. This new format, taken as a once-daily pill, will give a new option for those looking to take a GLP-1 long-term to help them manage their weight.
When comparing the Wegovy pill vs injection, there are numerous advantages for users, offering a powerful opportunity for patients to change how they manage their weight-loss regimen.
This article will cover:
- What is the Wegovy oral pill?
- How the Wegovy pill works
- The Wegovy pill data
- Wegovy pill vs Injection
And more.
What is the Wegovy oral pill?
In April of 2005, the first GLP-1 drug was approved by the FDA. Known as Byetta, the FDA-approved drug was prescribed to treat Type 2 diabetes. Over the next 20 years, a handful of new GLP-1 injections were approved and brought to market.
Some of the most famous include Ozempic, Rybelsus, and Wegovy. However, most of these medications were approved as injections for Type 2 diabetes, while Rybelsus was approved as an oral treatment for Type 2 diabetes.
Now, Novo Nordisk has changed the GLP-1 landscape by announcing the approval of its new oral pill, Wegovy, which will provide GLP-1 treatment to those seeking a GLP-1 for weight-loss management.
This is the first time a GLP-1 oral pill will be approved for on-label use in weight loss management.
How the Wegovy pill works
Much like Ozempic or Rybelsus, Wegovy is a semaglutide. The active ingredient in these drugs, semaglutide, has now been reformulated to be offered for daily oral dosing.
GLP-1s achieve weight-loss management through several mechanisms. GLP-1 signals the brain to feel full sooner, helping people eat less without feeling constantly hungry.
Not only that, but GLP-1s slow digestion by prolonging the time it takes for food to leave the stomach, helping maintain the full feeling for longer.
Plus, GLP-1s offer improved blood sugar regulation by stabilizing blood sugar levels and reducing cravings and energy spikes that can lead to overeating.
The medication’s role, combined with a reduced-calorie diet and increased physical activity, is shown in studies to help patients lose weight.
Those preferring pills to injections or wanting a simpler routine (every day vs once a week) may benefit from talking to their doctor about switching their GLP-1 from an injection to the recommended once-daily dose of Wegovy oral pill.
Weight loss results: What the clinical data shows
Results from the OASIS 4 phase 3 clinical trial suggest that the Wegovy oral pill may have a powerful effect. The study, which included 307 adults with obesity or overweight, reported an average weight loss of about 14% compared to placebo. This result was achieved with a reduced-calorie diet and exercise. Among patients who stayed on treatment, the average weight loss increased to 17%.
For those taking Wegovy, 76% achieved a loss of 5% of their body weight or more, compared with 31% of those taking a placebo.
Meanwhile, the placebo resulted in about 2-3% weight loss, illustrating the effect of the Wegovy oral pill on patients.
Wegovy pill vs injectable GLP-1 medications
The science behind Wegovy has long been proven in injectable form, but the oral pill can replicate the significant weight-loss outcomes seen with injectable GLP-1 medications.
Having a once-a-day pill may make the difference for some patients, allowing them to practice a simplified routine of once-daily dosing and skipping the tiresome, complex, and anxiety-inducing injection process.
Even though both forms leverage the same GLP-1 mechanism, the pill especially expands choices for both patients and providers.
Who is the Wegovy pill for?
Currently, the pill is geared towards adults with obesity or who are overweight with related medical conditions. Experts recommend that the pill be used alongside lifestyle changes, including diet and reduced-calorie diets.
However, Novo Nordisk reports not knowing whether semaglutide would be safe and effective for children under 12 to use when attempting to lose weight and keep it off. Likewise, it is not known whether the Wegovy pill is safe and effective for people under 18 years of age.
Side effects and safety considerations
Much like many other medications, some side effects may occur. Drawing from Novo Nordisk’s press release, common adverse reactions may occur. These common reactions are similar to those of the injectable form of Wegovy.
Some of those common side effects include:
- Nausea
- Diarrhea
- Vomiting
Patients should ask their doctor for a more complete list of possible side effects and discuss their tolerability with their healthcare provider. Also, those taking the medication should communicate with their healthcare provider regularly, notifying them of any changes in their health or condition.
Availability, cost, and access in the U.S.
The Wegovy oral pill is now available at 70,000+ U.S. pharmacies, including CVS and Costco. It is also available through select telehealth partners, including Ro, LifeMD, and Weight Watchers.
Patients looking to pay out of pocket can start on the 1.5mg dose at around $149 per month, with additional dosing options available at tiered prices.
Meanwhile, commercial insurance patients may pay as little as $25 per month when applying the savings offer.
What patients should know before starting
As always, patients should consult their doctor before making any treatment decisions.
Once prescribed, patients should always take their medication as prescribed and intended.
Recommendations also state that patients should maintain a reduced-calorie diet and exercise while taking the Wegovy GLP-1 pill for weight loss management.
Conclusion: What the Wegovy pill means for patients
Novo Nordisk has announced that the first oral GLP-1 weight-loss medication is now approved in the U.S., making it widely accessible to adults with obesity and related conditions.
Having an oral option helps patients choose from a broader range of GLP-1s for weight loss management and may improve accessibility and ease of use compared to injectables.
This milestone in pharmaceuticals will offer people a new, clinically supported tool to support significant weight loss as part of a healthy lifestyle.
And for those who are struggling to afford their GLP-1s, Prescription Hope may be able to help. Patients who qualify receive access to their brand-name medication for $70.00 per month, per medication. Without medication costs, contracts, or surprise fees, patients across the nation have benefited from Prescription Hope’s application, management, refill, and renewal services.
To enroll, simply fill out our online enrollment form, and a specialized staff member will contact you within 1-2 business days.